What was the primary purpose of these transactions?

The primary purpose was to refinance Medline's existing debt structure by issuing new notes and a new term loan facility. This was done to repay and refinance outstanding indebtedness, extend debt maturities, and optimize the company's capital structure.

What is the total amount of new debt issued?

Medline issued a total of $2.0 billion in new senior secured notes ($1.25 billion due 2031 and $750 million due 2033) and entered into a new approximately $2.75 billion senior secured term loan facility due 2033.

How will the proceeds from the new debt be used?

The net proceeds from the notes offering, along with borrowings from the new term loan facility and cash on hand, were used to repay in full an existing senior secured term loan facility due 2028, refinance a portion of the 2030 term loan facility, redeem a significant portion of the 2029 senior secured notes, and cover related fees and expenses.

What is the collateral backing these new notes?

The new notes are secured by substantially all assets of the Issuers and the guarantors that also secure the company's Senior Secured Credit Facilities and existing secured notes on a pari passu basis, subject to permitted liens. Prior to a specific event (Collateral Release Date), this includes security interests in capital stock of subsidiaries and certain tangible and intangible assets.

MDLN 8-K: Material Agreements & Financial Events

Summary

Medline Inc. (MDLN) has filed an 8-K report detailing significant refinancing transactions executed on May 28, 2026. The company successfully issued $2.0 billion in aggregate principal amount of new senior secured notes, comprising $1.25 billion of 5.000% notes due 2031 and $750 million of 5.250% notes due 2033. These proceeds, along with new term loan borrowings and cash on hand, were utilized to repay existing debt, including a senior secured term loan due 2028 and a portion of its 2030 term loan facility, as well as to redeem a portion of its 2029 senior secured notes. This strategic move aims to extend debt maturities, potentially lower interest costs, and improve its overall debt structure. In parallel, Medline also amended its credit agreement to refinance its existing senior secured term loan facility due 2030 with a new approximately $2.75 billion senior secured dollar-denominated term loan facility due 2033. The company also announced a public offering of Class A common stock by certain selling stockholders, raising approximately $2.68 billion. While the debt transactions focus on capital structure optimization, the equity offering reflects potential liquidity events for major shareholders.

Key Highlights

1Medline issued $1.25 billion in 5.000% senior secured notes due 2031 and $750 million in 5.250% senior secured notes due 2033, totaling $2.0 billion.
2Proceeds were used to repay outstanding debt, including a 2028 term loan, refinance a portion of the 2030 term loan, and redeem $500 million of 2029 senior secured notes.
3The company entered into a new $2.75 billion senior secured term loan facility due 2033, refinancing its prior facility.
4The new notes and term loan are secured on a pari passu basis with existing secured obligations, subject to permitted liens.
5The notes carry semi-annual interest payments on June 15 and December 15, with maturities in 2031 and 2033.
6A Change of Control Triggering Event may require the company to repurchase the notes at 101% of their principal amount.
7Certain selling stockholders completed a public offering of 72,554,594 shares of Class A common stock at $37.00 per share.

Medline Inc. 8-K Report, Material Agreement (Jun 2, 2026)

Summary

Key Highlights

Frequently Asked Questions